Topic
Drug Labeling
96 published works
Drug & Device Law
Adverse Event Reports Not Newly Acquired Information for CBE Label Change
Today’s case is a favorable prescription drug preemption decision making a key holding on newly acquired information and adverse event reporting. It is a one-off case involving the prescription drug…
Health Care and Life Sciences
Southern District of New York Puts Non-Drowsy Labeling Claims To Bed
It’s the start of cold and flu season, so why not talk about cough syrup. Most cough medicines come in two versions – daytime and nighttime. The nighttime version typically…
Drug & Device Law
Failure-to-Warn Claim Targeting Branded Drug Held Preempted: Litigation-Driven Expert Analysis Is Not “Newly Acquired Information” for Purposes of the “Changes Being Effected” Regulation
Under Wyeth v. Levine, 555 U.S. 555 (2009), and PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011), failure-to-warn claims targeting a pharmaceutical are preempted unless the manufacturer could have provisionally…
Drug Injury Watch
Beovu Drug Label Change in December 2021 Adds More Information About Vision Loss Side Effects
By Tom Lamb
Provides "risk factors and possible mechanism" for Beovu-related Retinal Vasculitis and Retinal Vascular Occlusion (Posted by Tom Lamb at Drug Injury Watch) We have finally seen the first Beovu drug label…
Drug & Device Law
D.N.J. Dismisses Drug Consumer Fraud Action on Preemption Grounds
A lot of life comes down to timing. Maybe you submitted your job application just as positions were opening. Maybe a slow taxi driver caused you to miss a disaster.…
Mass Tort Defense
Drug Claims Preempted – Lack of Newly Acquired Evidence
By Sean Wajert
Today's post looks at Rayes v. Novartis Pharms. Corp., No. EDCV21201JGBKKX, 2021 WL 2410677 (C.D. Cal. June 11, 2021), which contains an interesting discussion of an aspect of drug product preemption. …
Big Molecule Watch
Introduction To Biosimilars And Labeling Issues (For The Defense)
As biosimilars begin to gain traction in the U.S. pharmaceutical market, the distinct labeling requirements applicable to them are likely to affect product liability litigation in this area, raising implications…
Drug & Device Law
Guest Post – E-Gads, Once Again Preemption Prevails In Gadolinium Contrast Litigation
By Bexis
Here's another guest post by Reed Smith's Dean Balaes. This one looks into a major (but not too recent) post-Albrecht drug preemption case. Can't have too many of those! As…
Drug & Device Law
Guest Post – Paint It Black: The Ninth Circuit OKs RICO Liability For Failure To Warn About Drug Safety Risks
By Bexis
Today's guest post, about a bottom-ten RICO third-party payor action from (no surprise) the Ninth Circuit, is by long-time friend of the blog (and blogger in his own right), Jonah…
Drug & Device Law
Redistribute This!
By Bexis
Back in 2012, we published our “Distribute This!” post about In re Fosamax (Alendronate Sodium) Products Liability Litigation (No. II), 2012 WL 181411 (D.N.J. Jan. 17, 2012), lauding its ruling…